Provided are crystalline N-methyl-glucamine and sodium salts of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acetic acid, processes for their preparation, pharmaceutical compositions comprising the salts, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.
